Patient Recruitment Complete for High-Dose Cohort of Oral Fasudil in Phase 2 ALS Study

Published Date: 21 Nov 2024

Investigators are set to test the effects of 300 mg/day fasudil after the therapy showed promising data on ALS-related biomarkers in 180 mg/day doses.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New surgical method shows promising results for cervical cancer treatment

2.

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

3.

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

4.

Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer

5.

Can Prior Authorization Be Better With Artificial Intelligence?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot